Loading
RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Mainly associated with cytoskeleton organisation, in active state binds to a variety of effector proteins to regulate cellular responses such as cytoskeletal dynamics, cell migration and cell cycle. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibres.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.34, genetic association 0.03, somatic mutation 0.95). IntOGen calls it a driver in 14 cohorts (13 activating, 1 loss-of-function), covering Burkitt Lymphoma, Bladder Urothelial Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma, Malignant Lymphoma, Non-Hodgkin Lymphoma and others.
In plain words · RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.
RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state.
No product in this corpus aims at RHOA yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA RHOA: RNA low tissue specificity; no normal tissue stained high. Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Mesothelioma, Prostate cancer, Leukaemia); Open Targets associates it with 2 specific cancer types at or above 0.5 (Burkitt lymphoma, gastric adenocarcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P61586; CIViC gene RHOA; IntOGen RHOA; Human Protein Atlas RHOA tissue; Open Targets ENSG00000067560 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Yeramian et al, Nucleic Acids Res, 1987, "Nucleotide sequence of human rho cDNA clone 12". Source.
Sources: HGNC HGNC:667 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P61586 (protein name, function text, keywords and locations (REST API)); CIViC gene RHOA (3 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Stomach Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000067560 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: gastric cancer 0.65, urinary bladder cancer 0.56, non-Hodgkin lymphoma 0.72, Burkitt lymphoma 0.53, leukaemia 0.56 (GraphQL API, CC0)); IntOGen RHOA (driver in 14 cohorts (Act 13, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Mainly associated with cytoskeleton organisation, in active state binds to a variety of effector proteins to regulate cellular responses such as cytoskeletal dynamics, cell migration and cell cycle. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibres. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Location: Cell membrane; Cytoplasm, cytoskeleton; Cleavage furrow; Cytoplasm, cell cortex (UniProt). Locus 3p21.31 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Adipose tissue, Adrenal gland, Breast, Caudate, Cerebellum, Cerebral cortex and more.
No cancer stained high; medium in carcinoid, glioma, liver cancer, lung cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RHOA" OR ABSTRACT:"RHOA" OR TITLE:"ras homolog family member A" OR ABSTRACT:"ras homolog family member A" OR TITLE:"Transforming protein RhoA" OR ABSTRACT:"Transforming protein RhoA" OR TITLE:"Rho12" OR ABSTRACT:"Rho12" OR TITLE:"RHOH12" OR ABSTRACT:"RHOH12" OR TITLE:"ARH12" OR ABSTRACT:"ARH12") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RHOA, not a curated reading list.
Shares RHOA G17V, Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming.
Shares Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming, CIViC.
Shares Clonal haematopoiesis (CHIP), Leukaemia (all types), Bladder & urothelial cancer, CIViC.
Shares Leukaemia (all types), CIViC, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma.
Shares Mesothelioma, Leukaemia (all types), CIViC, IntOGen.
Shares Leukaemia (all types), Bladder & urothelial cancer, CIViC, IntOGen.
Shares RHOA G17V, Clonal haematopoiesis (CHIP), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Epigenetic reprogramming.
Shares Leukaemia (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.